
This study was a double-blind, randomized, placebo-controlled, multicenter, phase 2 clinical trial in mild to moderate COVID-19 patients. The study randomly assigned patients to receive either camostat mesylate (DWJ1248) or a placebo orally for 14 days. Camostat mesylate was safe in the treatment of COVID-19. Although this study did not show clinical benefit in patients with mild to moderate COVID-19, further clinical studies for high-risk patients are needed.
Like
Save
Share